Skip to content
Menu

Revolution Medicines, Inc. RVMD

Full chart Compare
Set alert

Price alert · RVMD

All alert types
161.20 USD +1.77 (+1.11%)

Regular-session close

162.08 +0.88 +0.55%

After hours · Nov 20, 6:57 PM ET

160.22 Day range 169.51
69.88 52-week range 221.15
YTD
+102.39%
1 year
+130.68%

5D -11.60 (-6.71%)

160165170MonTueWedThuFri161.20
Market cap
34.87B
Revenue (ttm)
197.56M
EPS (ttm)
-9.13
Shares out
216.29M
Forward P/E
-51.14
YTD return
+102.39%
1-year return
+130.68%
50-day average
190.87
200-day average
161.19
Enterprise value
32.04B
Volume
4.74M
Avg volume
2.24M
Open
161.61
Previous close
159.43
Day's range
160.22 – 169.51
52-week range
69.88 – 221.15
Beta
1.43
Analysts
Strong Buy
Price target
274.68 (+70.4%)
Earnings date
Feb 24, 2027

Key statistics

Price / sales
176.49
Price / book
14.52
Free cash flow
-886.29M
Total cash
3.65B
Total debt
1.21B
Return on equity
-93.56%
Short % of float
6.38%

Fundamental scorecard

4 of 25 checks passed on RVMD’s reported financials

ValueGrowthProfitabilityHealthDividend

4of 25 checks passed

  • Value 0 of 5
  • Growth 0 of 5
  • Profitability 1 of 5
  • Financial health 3 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
RVMD Revenue — quarterly 197.56M
RVMD Net income — quarterly -407.46M
RVMD EPS — quarterly -1.90

Earnings

RVMD recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 24, 2027Dec 30, 2026-1.16———
Nov 4, 2026Sep 30, 2026-2.35-1.90+0.45+19.15%
Aug 5, 2026Jun 30, 2026-2.04-3.06-1.02-50.00%
May 6, 2026Mar 31, 2026-1.84-2.29-0.45-24.46%
Feb 25, 2026Dec 31, 2025-1.58-1.86-0.28-17.72%
Nov 5, 2025Sep 30, 2025-1.42-1.61-0.19-13.38%

Upgrades / downgrades

RVMD analyst upgrades and downgrades
DateFirmActionFromTo
Nov 6, 2026HC Wainwright & Co.mainBuyBuy
Nov 5, 2026TD CowenmainBuyBuy
Nov 5, 2026RBC CapitalmainOutperformOutperform
Nov 5, 2026Piper SandlermainOverweightOverweight
Nov 5, 2026Truist SecuritiesreitBuyBuy
Nov 5, 2026GuggenheimmainBuyBuy

About Revolution Medicines, Inc.

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291) which is in early clinical development for the treatment of solid tumors, and zoldonrasib G12D (RMC-9805), which are in phase 3 registrational trial evaluating the combination of daraxonrasib with zoldonrasib in patients with 1L PDAC; and development candidates comprise RMC-5127 (G12V) which is in clinical trial, RMC-0708 (Q61H), that is in clinical trial; and RMC-8839 (G13C). Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Sector
Healthcare
Industry
Biotechnology
Country
United States
Website
revmed.com

News

Your note

Sign in to keep a note on RVMD — it syncs with the Stock Master app.

Insider holders

RVMD insider holders
InsiderRelationLatest transactionDateShares held
ANDERS JACK LEEChief Financial OfficerSaleNov 10, 2026119,216
BORISY ALEXISDirectorStock GiftNov 10, 20262,329,450
GOLDSMITH MARK AChief Executive OfficerSaleAug 20, 20260
HORN MARGARET AChief Operating OfficerSaleJun 16, 2026154,647
HORNING SANDRADirectorStock Award(Grant)Jun 17, 202697,765
KELSEY STEPHEN MICHAELOfficerSaleNov 15, 2026286,307

Institution ownership

RVMD institution ownership
Holder% heldSharesValueReported
FMR, LLC7.12%15,397,7142.48BSep 29, 2026
Blackrock Inc.6.41%13,857,3242.23BSep 29, 2026
Farallon Capital Management LLC6.20%13,418,7962.16BSep 29, 2026
Baker Bros. Advisors, LP4.92%10,637,3181.71BSep 29, 2026
Darwin Global Management, Ltd.4.91%10,629,8221.71BSep 29, 2026
Vanguard Capital Management LLC4.23%9,149,5341.47BSep 29, 2026

Fund ownership

RVMD fund ownership
Holder% heldSharesValueReported
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund2.96%6,412,4131.03BJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund2.14%4,631,150746.54MJun 29, 2026
Growth Fund of America1.37%2,964,768477.92MSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Small-Cap Growth Index Fund1.23%2,670,853430.54MJun 29, 2026
Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund1.14%2,472,885398.63MSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund1.06%2,291,511369.39MJun 29, 2026